Oppenheimer analyst Suraj Kalia maintained a Hold rating on Shockwave Medical (SWAV) today. The company’s shares closed last Wednesday at $86.91.
According to TipRanks.com, Kalia is a 4-star analyst with an average return of 4.5% and a 53.9% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Cardiovascular Systems.
Shockwave Medical has an analyst consensus of Moderate Buy, with a price target consensus of $93.80, representing a 0.2% upside. In a report released yesterday, Merrill Lynch also downgraded the stock to Hold with a $105.00 price target.
See today’s analyst top recommended stocks >>
Based on Shockwave Medical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $19.59 million and GAAP net loss of $12.93 million. In comparison, last year the company earned revenue of $11.33 million and had a GAAP net loss of $12.96 million.
Based on the recent corporate insider activity of 88 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Shockwave Medical, Inc. operates as a medical device company. It focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.
